OUR MISSION OUR EXPERTISE OUR SERVICES

Similar documents
NHLBI Gene Therapy Resources

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

ICH Considerations. Oncolytic Viruses September 17, 2009

IND - Cell Therapy. Robert W. Lindblad, MD, FACEP. Where Did you Hear

ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008

Global Leader in Viral Vector Technologies

ICH CONSIDERATIONS Oncolytic Viruses

Optimisation de votre programme de développement

Specialty Lab Services. Deep science at scale

AAV vectors for gene therapy. Any Gene to Any Cell

NIH-RAID: A ROADMAP Program

The Aptuit Center for Drug Discovery & Development Verona, Italy

Current situation on nonclinical safety evaluation of regenerative medical products in Japan

Expectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer

FDA Perspective on the Preclinical Development of Cancer Vaccines

Drug Development - Points to Consider

the PLATFORM Pipeline in Lyon AREA

Regulatory requirements for early stage clinical trials with cell-based medicinal products. Christopher A Bravery

CONTRACT RESEARCH SERVICES

R&D of Biological Products. Rochapon Wacharotayankun, Ph.D., R.Ph.

Cell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.

SPEED UP YOUR TIME TO MARKET

DMTC Technology Readiness Levels Guideline

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach

Development of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

Specifications. February 19, 2015, TOKYO, JAPAN. Takao Hayakawa, Ph.D. Director, Pharmaceutical Research and Technology Institute, Kindai University

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

Raw materials for cell & gene therapy: exploring regulatory and supply issues

Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer

US FDA: CMC Issues for INDs

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)

Quality & Safety GLP. 44 q&more 02/14

CMC Considerations for Stem Cell-based. Donald W. Fink, Jr., Ph.D.

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Production Assistance for Cellular Therapies PACT

UNLEASH THE POWER OF PRECISION MEDICINE

Pre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products

NaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER

Opportunities and Challenges for Manufacturing Scale Up of CAR T Cells. Mark Dudley Institute of Medicine March 1, 2016

Senior Regulatory Affairs Executive AREAS OF EXPERTISE

Comparability Is Not a Nightmare, Just Think Ahead!

Cell Therapy Services Your Product. Our Passion.

synlab clinical trial

Investigating Critical Challenges in the Gene Therapy Field

The Elite Provider. Cell & Gene. Therapy Manufacturing

My Potency Assay is Quantitative But is it Quantitative of Potency?

Considerations in Product Development with Advanced Therapies and Cancer Vaccines

TECHNOLOGY READINESS LEVELS (TRLs)

GUIDELINES FOR GENERATING PRE-CLINICAL AND CLINICAL DATA FOR r-dna BASED VACCINES, DIAGNOSTICS AND OTHER BIOLOGICALS, 1999

Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences

Departments of Biotechnology. Academic planner for (ODD semesters) Month I Semester III Semester V Semester

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

Justification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery

Detection of toxicity to reproduction for human pharmaceuticals. Explanatory slides agreed by EWG members

Cancer Research. Peptide Innovations in. Neo-Epitope Analysis Immunotherapy Cancer Proteomics Enzyme Profiling Epigenetics

Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will

Regulatory requirements for cell based medicinal products

Engage with us on Twitter: #Molecule2Miracle

PACIFIC RIM CONSULTING COMMENTS ON FDA PROPOSAL TO REVISE GLPS

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Structure and content of an IMPD. What is required for first into man trial?

10/07/2018. Liver directed gene therapy. - An overview. DNA/RNA therapies for Wilson s disease. The liver, organ of choice. Highly vascularised

COMMISSION DIRECTIVE 2009/120/EC

BIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University

Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment

International. Recruiting Briefing

CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS

Case Study: Examples Relating to the Quality Control of Cell-based Products

Federal agency for medicines and health products

Nanotechnology and Advanced Materials for more effective Healthcare

Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016

CMC Considerations for Manufacturing of CAR T-Cell Product

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) <DRAFT>

New proposal from the EC:

GMO Technology Conference

Some challenges in the development of new toxicity assays using in vitro methods

EC REVIEW OF THE ATMP REGULATION CELL THERAPY CATAPULT RESPONSES

Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies

Sanitary Authorisation Commission

Guideline on the non-clinical requirements for radiopharmaceuticals

The Molecular Virology Support Core: Adenoviral Vectors and Beyond

GMP. Safeguard The Patient s Health.

Asterand Bioscience Strategic Alliances

Clinical trial applications in the EU and US

DRUG REGISTRATION REGULATION

The Swedish Foundation for Strategic Research (SSF) announces a. call for proposals in the areas of

Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective

ICH 교육가이드라인 [ 안전성 & 품질 ]

Position Description November 2018

Developing New GM Products and Detection Methods

Recent years have witnessed an expansion in the disciplines encompassing drug

Lentiviral Vector Reference Material (LVV RM) Request for Proposal RFP 1.0 Vector Production and Purification

Transcription:

Capacités Biotherapeutics Solutions (C.B.S) is a newly created business unit of CAPACITÉS LLC, an affiliate company of the University of Nantes (France). By gathering experts and core facilities, C.B.S proposes to biotechnology, pharmaceutical companies and academic teams, a one-stop shop at all stages of their gene therapy preclinical developments. 1

OUR MISSION C.B.S is assisting biotech and academic entities to implement and de-risk preclinical development for their gene therapy programs. C.B.S provides access to the scientific expertise of the gene therapy institute and core facilities of Nantes. OUR EXPERTISE C.B.S provides assistance at all steps of gene therapy preclinical developments OUR SERVICES 2

Translational Vector Core Production Production of research grade AAV and adenoviral vectors In vitro/in vivo assays & proof of concept in small/large animal models 400 lots/year R&D High yield custom made processes for the production of AAV vectors Analytical methods: potency, purity, identity Transfer of GMP compatible manufacturing processes for viral vectors Gene Therapy Immunology Core G.T.I Large expertise in monitoring of host immunity in preclinical and clinical gene therapy protocols Participation in preclinical studies performed in rodent, canine and non-human primate models Monitoring of humoral & cellular immunity against viral vectors (AAV, adenoviral) and transgene products Large panel of validated assays including cell isolation, cell phenotyping, ELISA, ELISpot, Western Blot, cytokine detection GCLP guidelines for studies with regulatory requirements (clinical trials and Tox studies) Quality Assurance system approved for Iso9001 standard since 2006 3

Preclinical Analytics Core P.A.C Evaluation of in vitro & in vivo functionality of therapeutic reagents, including gene therapy products Evaluation of gene therapy product biodistribution & shedding by qpcr following in vivo administration Evaluation of gene therapy product expression profile by RT-qPCR & Western-Blot following in vivo administration High expertise in preclinical studies performed in rodent, canine and non-human primate models, including toxicological gene therapy studies Pathological Core APEX Expertise in Pathology 15 years of practice in analyzing genetically-modified tissues In a large spectrum of animal species Synergy between expertise in morphology, pathology, fluorescence imaging & molecular biology on slides Integrated offer for tissue Phenotyping - Tissue sampling & trimming - Topographic staining - Immunostaining and histoenzymology - in situ hybridization - Fluorescence bio imaging - Histomorphometry 2 veterinary pathologists (ECVP diplomates) including a neuropathologist Quality Assurance system approved for Iso9001 standard since 2006 4

Animal Core Facility Animal Core Facility 1600m2 (+350m2 office) Animal models housing and keeping including breeding of rare colonies Preclinical studies for gene & cell therapy and pharmacologic products Large expertise in rare animal models of genetic diseases Synergy and complementarity with external medical specialists CAPACITÉS Biotherapeutics Solutions (CBS) Your needs Our services Our experts Making strategic decisions Selecting vector technology Reviewing your preclinical data Designing your preclinical data Accesing your regulatory documents 20 years of expertise in gene therapy AAV production Baculovirus/Transfection Proof-of-concept, Product-design, Process development, Analytics GMO risk assessment, ODD, IMPD- CTD Dose-finding, Toxicology & biodistribution studies in vivo models Experts in gene therapy Experts in preclinial & clinical immunomonitoring EMA board certified pathologist with more than 10 years experience Experts in regulatory requirements Experts in IND submissions 5